Cytochrome P450 Pharmacogenetics in Drug Development: In Vitro Studies and Clinical Consequences

Author(s): A. David Rodrigues, Thomas H. Rushmore

Journal Name: Current Drug Metabolism

Volume 3 , Issue 3 , 2002

Become EABM
Become Reviewer
Call for Editor


Members of the human cytochrome P450 (CYP) superfamily play a role in the metabolism of many drugs and several of them, CYP2D6, CYP2C9 and CYP2C19, have been shown to be polymorphic as a result of single nucleotide polymorphisms (SNPs), gene deletions, and gene duplications. These polymorphisms can impact the pharmacokinetics (PK), metabolism, safety and efficacy of drugs, and because of the availability of automation, genotyped human tissue, recombinant CYP preparations (rCYPs) and reagents, most pharmaceutical companies have increasingly screened out compounds that are metabolized solely by polymorphic CYPs. In the absence of suitable animal models, it has been widely accepted that such in vitro data are useful because one can obtain information prior to dosing in man and select the most appropriate clinical studies with prospectively genotyped and phenotyped subjects. Overall, current trends in the industry have been fueled by increased managed healthcare, the desire to minimize the need for thera peutic drug monitoring and CYP genotyping in medical practice, and a very competitive market place. In the past, such paradigms have not been as influential and there are numerous examples of marketed drugs that are metabolized by polymorphic CYPs.

Keywords: p450, cyp, cyp2d6, cyp2c9, cyp2c19, snps

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2002
Published on: 01 March, 2012
Page: [289 - 309]
Pages: 21
DOI: 10.2174/1389200023337522
Price: $65

Article Metrics

PDF: 9